London, UK – December 10, 2024
Relation, a leader in computational and experimental drug discovery, has announced two strategic collaborations with GSK focused on identifying and validating novel therapeutic targets for fibrotic diseases and osteoarthritis. These chronic conditions affect millions globally and represent major areas of unmet medical need.
Financial Terms and Milestones
Under the terms of the agreement, Relation will receive:
- $45 million upfront from GSK, including a $15 million equity investment
- Eligibility for up to $63 million in success-based collaboration payments
- Milestone payments averaging $200 million per target
- Tiered royalties on net sales from any resulting products
Leveraging AI-Driven Discovery
“These diseases currently have limited treatment options that address their root causes,” said David Roblin, CEO of Relation.
“By combining Relation’s patient-centric discovery platform with GSK’s global expertise, we aim to accelerate the development of transformative medicines for patients who have long awaited new therapies.”
Relation’s approach utilizes patient-derived tissue data to construct a systems-level understanding of disease biology. By integrating artificial intelligence (AI) and machine learning with functional datasets, the company strengthens both target discovery and validation, helping reduce clinical failure risks.
AI-Powered Research and Development Approach
As part of the collaboration, Relation will lead observational studies to create functional disease datasets. These will be analyzed by its AI-powered Lab-in-the-Loop™ platform, which incorporates:
- Human genetics
- Single-cell multi-omics
- Functional assays
- Machine learning techniques
GSK will retain global development and commercialization rights for any therapies developed from these efforts.
Expert Perspectives
“Working with Relation allows us to gain deep insights into human disease biology and apply AI-powered data-driven approaches to therapeutic discovery,” said Kaivan Khavandi, SVP and Global Head of Respiratory/Immunology R&D at GSK.
“The validated targets emerging from these collaborations will support our broader efforts to develop new medicines for fibrotic diseases and osteoarthritis, areas of critical need.”
About Relation Therapeutics
Relation Therapeutics is a biotechnology company using its AI-enhanced Lab-in-the-Loop™ platform to discover treatments for complex diseases. Its platform integrates advanced technologies including human genetics, multi-omics, functional biology, and machine learning. The company focuses on metabolic and immune diseases and has raised over $80 million from top-tier investors, including DCVC, Magnetic, GSK, NVIDIA NVentures, Hitachi Ventures, Khosla, ARK Ventures, and Deerfield.
More on this news
By